Norman Wasel
Probity Medical Research(CA)Novartis (Canada)(CA)
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Autoimmune Bullous Skin Diseases, Dermatology and Skin Diseases, Dermatologic Treatments and Research, Hair Growth and Disorders
Most-Cited Works
- → Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials(2014)1,933 cited
- → A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial(2019)168 cited
- → Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet(2010)110 cited
- → Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study(2008)87 cited
- → Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis(2016)82 cited
- Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.(2013)
- → A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis(2010)39 cited
- → Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)(2020)39 cited
- → 2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009(2016)35 cited
- → A Two-Compound Product Containing Calcipotriol and Betamethasone Dipropionate Provides Rapid, Effective Treatment of Psoriasis vulgaris regardless of Baseline Disease Severity(2005)28 cited